The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Hengrui Medicine; Hengrui Medicine; Hengrui Medicine; Hengrui Medicine; Merck; Merck; Merck; Merck
Research Funding - Hengrui Medicine (Inst); Hengrui Medicine (Inst); Hengrui Medicine (Inst); Hengrui Medicine (Inst)
Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).
 
Daniel V.T. Catenacci
Honoraria - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genmab; Genmab; Genmab; Genmab; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; NantWorks; NantWorks; NantWorks; NantWorks; OncoPlex Diagnostics; OncoPlex Diagnostics; OncoPlex Diagnostics; OncoPlex Diagnostics; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Merck; Merck; Merck; Merck
 
Minori Koshiji Rosales
Employment - Macrogenics; Macrogenics; Macrogenics; Macrogenics
Stock and Other Ownership Interests - Macrogenics; Macrogenics; Macrogenics; Macrogenics
 
Jon M. Wigginton
Employment - Macrogenics; Macrogenics; Macrogenics; Macrogenics
Leadership - Macrogenics; Macrogenics; Macrogenics; Macrogenics
Stock and Other Ownership Interests - Macrogenics; Macrogenics; Macrogenics; Macrogenics
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celltrion; Celltrion; Celltrion; Celltrion; Gloria Biosciences; Gloria Biosciences; Gloria Biosciences; Gloria Biosciences; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Quintiles; Quintiles; Quintiles; Quintiles; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Foundation medicine; Foundation medicine; Foundation medicine; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Harry H. Yoon
Honoraria - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; BeiGene; BeiGene; BeiGene; BeiGene; LSK Biopharma; LSK Biopharma; LSK Biopharma; LSK Biopharma; Macrogenics; Macrogenics; Macrogenics; Macrogenics; Merck; Merck; Merck; Merck
Research Funding - Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Lilly/ImClone (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly; Lilly; Lilly; Lilly
 
Lin Shen
No Relationships to Disclose
 
Markus H. Moehler
Honoraria - Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Servier; Servier; Servier; Servier; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Nordic Group; Nordic Group; Nordic Group; Nordic Group; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Jennerex (Inst); Jennerex (Inst); Jennerex (Inst); Jennerex (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; ASCO; ASCO; ASCO; ASCO; Bayer; Bayer; Bayer; Bayer; ESMO; ESMO; ESMO; ESMO; German Cancer Society; German Cancer Society; German Cancer Society; German Cancer Society; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche
 
Yoon-Koo Kang
No Relationships to Disclose